Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2020

View Archived Issues

Carbon dioxide and the brain

Researchers report identification of TQ-05310, a novel potent mutant IDH2 inhibitor

First-in-human data published for the pan-PIM kinase inhibitor PIM-447

Murine CD16.28z CAR iNKT cells exert both direct and indirect antitumor effects in vivo

Preliminary data from phase III ASCERTAIN study of ASTX-727

CohBar discovers novel peptide inhibitors of CXCR4

FDA clears IND for ADXS-504 as treatment of prostate cancer

Positive topline data from phase Ib study of CBP-201 in moderate to severe atopic dermatitis

Topline data from pivotal phase II portion of the ACTION-Galactosemia study

SR-4835, a novel CDK12/13 dual inhibitor for treating triple-negative breast cancer

Abbisko Therapeutics divulges FGFR-1 and/or FGFR-2 inhibitors

New treatment discovered for heart tissue scarring after infarct

Novartis presents new compounds for dengue

FDA clears Carmell's IND for pivotal study of BHA for open tibia fractures

Bone Biologics' rhNELL-1 growth factor promotes bone formation in preclinical study

Merck & Co. identifies new arginase inhibitors

ViiV Healthcare UK describes HIV integrase inhibitors

Eli Lilly and Company patents OGA inhibitors

Scynexis reports new phase III interim data with ibrexafungerp in invasive fungal infections

Blueprint releases topline data for pralsetinib in RET fusion-positive NSCLC

Agenus begins phase I study with bispecific antibody AGEN-1223

DBV reports data from open-label extension study of Viaskin Peanut

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...